The waiting room, as it turns out, is now on your phone.
Flok Health, a Cambridge-based startup that claims to have built the world's first fully autonomous AI physiotherapist, announced on June 3, 2026 it had closed a $12.5 million Series A round. More telling than the funding itself: the company already treats over 2.4 million NHS patients across eleven regions in a health system famously strapped for time and money.
AlbionVC led the oversubscribed round, joined by existing backers Eka Ventures and Form Ventures, along with newcomer Mercia Ventures. The capital will fund Flok's expansion across the UK—scaling its AI-operated back pain service while launching new treatment pathways for hip, knee, and women's pelvic health issues later this year. International markets, the company says, are also under consideration.
A Regulatory First (and a Risky Bet)
What makes Flok unusual isn't just that it deploys AI in healthcare—everyone does that now. It's that the company secured something competitors haven't: regulatory permission to let the algorithm make clinical decisions entirely on its own.
In October 2025, Flok is set to become the first digital musculoskeletal service in the UK and Europe to receive Class IIa medical device clearance for autonomous clinical decision-making. The UKCA and CE markings allow its AI system to assess, diagnose, and treat patients without human clinician oversight at critical junctures. Other digital MSK platforms typically require a therapist in the loop when decisions get consequential.
Flok also registered with the UK's Care Quality Commission, a step the company insists sets it apart in a crowded digital MSK field. Whether that's genuinely unique or clever positioning depends on whom you ask.
How It Works (and Whether Patients Actually Use It)
The service operates through a mobile app where patients interact with a digital physiotherapist constructed from real clinician footage. The AI responds in real time to patient inputs—what they say, how they move—creating what the company describes as more than a billion possible treatment combinations. That figure sounds precise enough to be marketing copy, but the underlying claim is straightforward: this isn't a one-size-fits-all chatbot.
Flok's proof of concept came during a twelve-week pilot at Cambridgeshire Community Services NHS Trust between February and June 2025. The service enrolled over 2,500 patients and reduced back pain waiting lists by about 50 percent. Overall MSK wait times at the trust fell by 44 percent. By February 2026, the service had rolled out to eleven NHS regions.
Recent deployment data suggests patient acceptance is high, though perhaps more than the founders initially expected. More than 80 percent of users rate the AI clinic as good as or better than in-person physiotherapy. At one trust, the service saves an average of 856 clinical hours per month. And here's the number that likely caught investor attention: 98.5 percent of back pain patients complete their full treatment pathway through the AI alone, with no need to escalate to a human clinician.
That completion rate is either a sign of clinical effectiveness or a reflection of how desperate patients are for any care at all in an overstretched system. Likely both.
The Competitive Landscape (It's Crowded)
Flok is hardly alone in the digital MSK market. The space is dominated by US giants Hinge Health, which went public in May 2025 at a $4.28 billion market cap, and Sword Health, valued at $4 billion as of June 2025 and fresh off a $285 million acquisition of Kaia Health in January 2026. Both companies have deep pockets, established distribution channels, and years of clinical validation.
Flok's wager—and it is a wager—is that truly autonomous AI can deliver comparable clinical outcomes at price points the NHS can stomach. The Series A funding gives the company runway to test that thesis at scale while pushing beyond back pain into other high-volume musculoskeletal conditions.
Founded in 2022 by former professional rower Finn Stevenson and technologist Ric da Silva, Flok previously raised roughly £3.2 million in October 2025 from Eka Ventures, Form Ventures, and Paul Forster, co-founder of Indeed. The new round more than triples its total capital and positions the company for what could be a defining year: prove the model works across multiple conditions and geographies, or risk being swallowed by better-capitalized competitors with similar ambitions.
The NHS, at least for now, seems willing to let the experiment run. Whether that's visionary or pragmatic remains to be seen.
